Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40581 |
TIE-2/VEGFR-2 kinase-IN-2
|
||
TIE-2/VEGFR-2 kinase-IN-2 is a powerful inhibitor of both VEGFR2 and Tie-2 kinases, displaying noteworthy pIC 50 values of 8.61 and 8.56, respectively. This compound acts as an anti-angiogenic agent, making it highly relevant for cancer research. | |||
T8817 |
TIE-2/VEGFR-2 kinase-IN-1
|
||
TIE-2/VEGFR-2 kinase-IN-1 用于合成TIE-2或者VEGFR-2抑制剂,可用于研究不适当的血管生成的相关疾病。 | |||
T79860 |
TIE-2/VEGFR-2 kinase-IN-5
|
VEGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
TIE-2/VEGFR-2 kinase-IN-5 是一种高效的 TIE-2 和 VEGFR-2 酪氨酸激酶受体抑制剂,具有的抗血管生成活性,常用于血管生成相关的生物医学研究领域。 | |||
T16724 |
Razuprotafib
AKB-9778 |
Phosphatase; Others | Metabolism; Others |
Razuprotafib (AKB-9778) 是一种 VE-PTP (HPTPß)催化活性的有效选择性抑制剂,抑制结构相关磷酸酶 PTP1B。除 HPTPη 和 HPTPγ 外,它对 VE-PTP 具有良好的选择性。它能够促进 TIE2 活化,增强 ANG1 诱导的 TIE2 活化,并刺激 TIE2 通路中信号分子的磷酸化。 | |||
T6335 |
Tie2 kinase inhibitor 1
Tie2 kinase inhibitor |
Tie-2 | Tyrosine Kinase/Adaptors |
Tie2 kinase inhibitor 1 (Tie2 kinase inhibitor) 是Tie2激酶选择性抑制剂9IC50:250 nM),具有抗癌作用。 | |||
T36718 |
Tie2 Inhibitor 7
|
||
Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization. | |||
T79859 |
TIE-2/VEGFR-2 kinase-IN-4
|
||
TIE-2/VEGFR-2 kinase-IN-4,一种苯并咪唑衍生物,作为有效的TIE-2和VEGFR-2酪氨酸激酶受体抑制剂,其IC50值分别为5.2 nM和5.1 nM,适用于血管生成相关研究。 | |||
T79858 |
TIE-2/VEGFR-2 kinase-IN-3
|
||
TIE-2/VEGFR-2 kinase-IN-3,为苯并咪唑衍生物,具备高效的抑制作用于TIE-2与VEGFR-2受体酪氨酸激酶,其IC50值分别达到6.9 nM和3.5 nM。本化合物主要用于血管生成相关研究。 | |||
T22259 |
AMG-Tie2-1
AMG-Tie2,4-甲基-3-[[3-[2-(甲基氨基)-4-嘧啶基]-2-吡啶基]氧基]-N-[3-(三氟甲基)苯基]苯甲酰胺 |
Others | Others |
AMG-Tie2-1 is a dual inhibitor of VEGF receptor 2 (VEGFR2) and tunica interna endothelial cell kinase 2 (Tie2). | |||
T6934 |
Pexmetinib
ARRY-614 |
Tie-2; p38 MAPK; Autophagy | Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Pexmetinib (ARRY-614) 是一种口服生物可利用的双重 p38 MAPK/Tie-2 抑制剂,可研究急性骨髓性白血病。在 HEK-293 细胞系中的 IC50 为 4 nM/18 nM。 | |||
T38930 |
BAY-826
|
Tie-2 | Tyrosine Kinase/Adaptors |
BAY-826 是一种新型、高效且具有选择性的 TIE-2 抑制剂,抑制 TIE-2 磷酸化,可用于研究肿瘤。 | |||
T4318 |
EOC317
ACTB-1003,ACTB1003,ACTB 1003 |
VEGFR; FGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
EOC317 (ACTB-1003) 是一种口服可用的激酶抑制剂,能够抑制 FGFR1 (IC50:6 nM),VEGFR2 (IC50:2 nM) 和 Tie-2 (IC50:4 nM)。 | |||
T2640 |
Rebastinib
DCC2036,DCC 2036,DCC-2036 |
Apoptosis; FLT; Bcr-Abl; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Rebastinib (DCC-2036) 是一种口服有效的,非 ATP 竞争性的 Bcr-Abl 抑制剂,作用于 Abl1WT 和 Abl1T315I,IC50分别为 0.8 nM 和 4 nM,还抑制 LYN、SRC、HCK、FGR、FLT3、KDR 和 Tie-2,对 c-Kit 的活性低。Rebastinib 对 Angiopoietin2-Tie2通路具有抑制作用。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
T71979 |
TP-S1-68
|
||
TP-S1-68 is a Type-I inhibitor of TIE-2. | |||
T11519 |
GW768505A free base
|
Others | Others |
GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity. | |||
T68484 | 2-MT-63 | ||
2-MT 63 is a novel TIE-2 kinase inhibitor that demonstrates unique and improved kinase selectivity compared to other inhibitors known to interact with TIE-2. 2-MT 63 has a good kinase selectivity profile in enzyme assays with >30-fold selectivity (typically much greater) against the tested kinases. Importantly, the profile includes selectivity against other targets of relevance for angiogenesis (KDR, PDGFR, EPHB4). | |||
T71819 |
RK-20448
|
||
RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R, and Tie-2. It also inhibits BLK, Csk, Fyn, and Lyn. RK-20448 is the cis isomer of A-419259 | |||
T68389 | LY2457546 | ||
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 synge... |